Alopecia areata

  • Pia Freyschmidt-Paul
  • Kevin McElwee
  • Rolf Hoffmann


Human Leukocyte Antigen Major Histocompatibility Complex Class Hair Follicle Hair Loss Human Leukocyte Antigen Class 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abell E, Munro DD (1973) Intralesional treatment of alopecia areata with triamcinolone acetonide by jet injector. Br J Dermatol 88: 55–9PubMedGoogle Scholar
  2. Ablamunits V, Elias D, Cohen IR (1999) The pathogenicity of islet-infiltrating lymphocytes in the non-obese diabetic (NOD) mouse. Clin Exp Immunol 115: 260–7CrossRefPubMedGoogle Scholar
  3. Alsaleh QA, Nanda A, al-Hasawi F, el-Kashlan M (1995) Concurrent appearance of alopecia areata in siblings. Pediatr Dermatol 12: 285–6PubMedGoogle Scholar
  4. Anderson I (1950) Alopecia areata: A clinical study. Br Med J 2: 1250–2.Google Scholar
  5. Andrade M de, Jackow CM, Dahm N, Hordinsky M, Reveille JD, Duvic M (1999) Alopecia areata in families: Association with the HLA locus. J Invest Dermatol Symp Proc 4: 220–3Google Scholar
  6. Annacker O, Pimenta-Araujo R, Burlen-Defranoux O, Barbosa TC, Cumano A, Bandeira A (2001) CD25+ CD4+ T cells regulate the expansion of peripheral CD4 T cells through the production of IL-10. J Immunol 166: 3008–18PubMedGoogle Scholar
  7. Averbakh EV, Pospelov LE (1986) HLA antigens in patients with alopecia areata. Vestn Dermatol Venerol 1: 24–6PubMedGoogle Scholar
  8. Barber HW (1921) Alopecia areata. Br J Dermatol and Syph 33: 1–14Google Scholar
  9. Bastos Araujo A, Poiares Baptista A (1967) Algunas consideracions sobre 300 casos de pelada. Trabalhos da Sociedad Portugesa de Dermatologia e Venereolagia 25: 135–41Google Scholar
  10. Behrens-Williams S, Leiter U, Schiener R, Weidmann M, Peter RU, Kerscher M (2001) The PUVA-turban as a new option of applying a dilute psoralen solution selectively to the scalp of patients with alopecia areata. J Am Acad Dermatol 44: 248–252CrossRefPubMedGoogle Scholar
  11. Betterle C, Greggio NA, Volpato M (1998) Clinical review 93 Autoimmune polyglandular syndrome type 1. J Clin Endocrinol Metab 83: 1049–55CrossRefPubMedGoogle Scholar
  12. Bigazzi PE (1994) Autoimmunity and heavy metals. Lupus 3:449–53PubMedGoogle Scholar
  13. Bodemer C, Peuchmaur M, Fraitaig S, Chatenoud L, Brousse N, De Prost Y (2000) Role of cytotoxic T cells in chronic alopecia areata. J Invest Dermatol 114: 112–6CrossRefPubMedGoogle Scholar
  14. Bonjean M, Prime A, Avon P. Pelade chez deux jumeaux homozygotes (sic) (1968) Lyon Med 219: 1852–3PubMedGoogle Scholar
  15. Bröcker EB, Echternacht-Happle K, Hamm H, Happle R (1987) Abnormal expression of class I and class II major histocompatibility antigens in alopecia areata: Modulation by topical immunotherapy. J Invest Dermatol 88: 564–8CrossRefPubMedGoogle Scholar
  16. Brown WH (1929) The aetiology of alopecia areata and its relationship to vitiligo and possibly scleroderma. Br J Dermatol and Syph 41: 299–323Google Scholar
  17. Burton JL, Shuster S (1975) Large doses of glucocorticoid in the treatment of alopecia areata. Acta Derm Venereol (Stockh) 55: 493–6PubMedGoogle Scholar
  18. Camacho F Anagenic and telogenic effluvia (1997) In: Trichology: Diseases of the pilosebaceous follicle, Camacho F, Montagna W, eds.; Aula Medica Group: Madrid pp. 387–96Google Scholar
  19. Carroll JM, McElwee KJ, E King L, Byrne MC, Sundberg JP (2002) Gene array profiling and immunomodulation studies define a cell-mediated immune response underlying the pathogenesis of alopecia areata in a mouse model and humans. J Invest Dermatol 119:392–402CrossRefPubMedGoogle Scholar
  20. Carter DM, Jegasothy BV (1976) Alopecia areata and Down syndrome. Arch Dermatol 112:1397–9CrossRefPubMedGoogle Scholar
  21. Case PC, Mitchell AJ, Swanson NA, Vanderveen EE, Ellis CN, Headington JT (1984) Topical therapy of alopecia areata with squaric acid dibutylester. J Am Acad Dermatol 10:447–51PubMedGoogle Scholar
  22. Caserio RJ (1987) Treatment of alopecia areata with squaric acid dibutylester. Arch Dermatol 123: 1036–41CrossRefPubMedGoogle Scholar
  23. Chan LS, Vanderlugt CJ, Hashimoto T, Nishikawa T, Zone JJ, Black MM, Wojnarowska F, Stevens SR, Chen M, Fairley JA, Woodley DT, Miller SD, Gordon KB (1998) Epitope spreading: lessons from autoimmune skin diseases. J Invest Dermatol 110: 103–9CrossRefPubMedGoogle Scholar
  24. Charuwichitratana S, Wattanakrai P, Tanrattanakorn S (2000) Randomized double-blind placebo-controlled trial in the treatment of alopecia areata with 0.25% desoximetasone cream. Arch Dermatol 136: 1276–1277CrossRefPubMedGoogle Scholar
  25. Claudy AL, Gagnaire D (1983) PUVA treatment of alopecia areata. Arch Dermatol 119: 975–8CrossRefPubMedGoogle Scholar
  26. Cole GW, Herzlinger D (1984) Alopecia universalis in identical twins. Int J Dermatol 23: 283PubMedGoogle Scholar
  27. Colombe BW, Price VH, Khoury EL, Garovoy MR, Lou CD (1995) HLA class II antigen associations help define two types of alopecia areata. J Am Acad Dermatol 33: 757–64PubMedGoogle Scholar
  28. Colombe BW, Lou CD, Price VH (1999) The genetic basis of alopecia areata: HLA associations with patchy alopecia areata versus alopecia totalis and alopecia universalis. J Invest Dermatol Symp Proc 4: 216–9Google Scholar
  29. Colon EA, Popkin MK, Callies AL, Dessert NJ, Hordinsky MK (1991) Lifetime prevalence of psychiatric disorders in patients with alopecia areata. Compr Psychiatry 32: 245–51CrossRefPubMedGoogle Scholar
  30. Cork MJ, Crane AM, Duff GW (1996) Genetic control of cytokines: Cytokine gene polymorphisms in alopecia areata. Dermatol Clin 14: 671–8CrossRefPubMedGoogle Scholar
  31. Cotellessa C, Peris K, Caracciolo E, Mordenti C, Chimenti S (2001) The use of topical diphenylcyclopropenone for the treatment of extensive alopecia areata. J Am Acad Dermatol 44: 73–6PubMedGoogle Scholar
  32. Cunliffe WJ, Hall R, Stevenson CJ, Weightman D (1969) Alopecia areata, thyroid disease and autoimmunity. Br J Dermatol 81: 877–81PubMedGoogle Scholar
  33. De Waard-van der Spek FB, Oranje AP, De Raeymaecker DM, Peereboom-Wynia JD (1989) Juvenile versus maturity-onset alopecia areata — a comparative retrospective clinical study. Clin Exp Dermatol 14:429–33PubMedGoogle Scholar
  34. De Weert J, Temmerman L, Kint A (1984) Alopecia areata: A clinical study. Dermatologica 168: 224–9PubMedGoogle Scholar
  35. Dillaha CJ, Rothman S (1952) Therapeutic experiments in alopecia areata with orally administered cortisone. J Am Med Ass 150:546–50Google Scholar
  36. Du Vivier A, Munro DD (1975) Alopecia areata, autoimmunity, and Down’s syndrome. Br Med J I: 191–2Google Scholar
  37. Duvic M, Hordinsky MK, Fiedler VC, O’Brien WR, Young R, Reveille JD (1991) HLA-D locus associations in alopecia areata. Arch Dermatol 127: 64–8CrossRefPubMedGoogle Scholar
  38. Duvic M, Welsh EA, Jackow C, Papadopoulos E, Reveille JD, Amos C (1995) Analysis of HLA-D locus alleles in alopecia areata patients and families. J Invest Dermatol 104(suppl):5S–6SPubMedGoogle Scholar
  39. Eichmüller S, van der Veen C, Moll I, Hermes B, Hofmann U, Muller-Rover S, Paus R (1998) Clusters of perifollicular macrophages in normal murine skin: physiological degeneration of selected hair follicles by programmed organ deletion. J Histochem Cytochem 46:361–70PubMedGoogle Scholar
  40. Elenkov IJ, Chrousos GP (2002) Stress hormones, proinflammatory and antiinflammatory cytokines, and autoimmunity. Ann N Y Acad Sci 966:290–303PubMedGoogle Scholar
  41. Elkayam O, Yaron M, Caspi D (1999) Minocycline-induced autoimmune syndromes: an over-view. Semin Arthritis Rheum 28: 392–7CrossRefPubMedGoogle Scholar
  42. Fiedler-Weiss VC, West DP, Buys CM, Rumsfield JA (1986) Topical minoxidil dose-response effect in alopecia areata. Arch Dermatol 122:180–82CrossRefPubMedGoogle Scholar
  43. Finnish-German APECED Consortium (1997) An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains. Nature Genet 17:399–403Google Scholar
  44. Fransway AF, Muller SA (1988) 3 percent topical minoxidil compared with placebo for the treatment of chronic severe alopecia areata. Cutis 41: 431–435PubMedGoogle Scholar
  45. Frentz G (1977) Topical treatment of extended alopecia. Dermatologica 155: 147–154PubMedGoogle Scholar
  46. Frentz G (1985) Topical minoxidil for extended areate alopecia. Acta Derm Venereol 65: 172–175PubMedGoogle Scholar
  47. Frentz G, Thomsen K, Jakobsen BK, Svejgaard A (1986) HLA-DR4 in alopecia areata. J Am Acad Dermatol 14: 129–30PubMedGoogle Scholar
  48. Freyschmidt-Paul P, Sundberg JP, Happle R, McElwee KJ, Metz S, Boggess D, Hoffmann R (1999) Successful treatment of alopecia areata-like hair loss with the contact sensitizer squaric acid dibutylester (SADBE) in C3H/HeJ mice. J Invest Dermatol 113: 61–8PubMedGoogle Scholar
  49. Freyschmidt-Paul P, Hoffmann R, Levine E, Sundberg JP, Happle R, McElwee KJ (2001) Current and potential agents for the treatment of alopecia areata. Curr Pharm Des 7: 213–30CrossRefPubMedGoogle Scholar
  50. Freyschmidt-Paul P, McElwee KJ, Botchkarev V, Kissling S, Wenzel E, Sundberg JP, Happle R, Hoffmann R (2003) Fas-deficient C3.MRL-Tnfrsf6(lpr) mice and Fas ligand-deficient C3H/HeJ-Tnfsf6(gld) mice are relatively resistant to the induction of alopecia areata by grafting of alopecia areata-affected skin from C3H/HeJ mice. J Investig Dermatol Symp Proc 8:104–8CrossRefPubMedGoogle Scholar
  51. Freyschmidt-Paul P, Zoeller M, McElwee KJ, Sundberg JP, Hoffmann R (2004) Th-1 cytokines in alopecia areata pathogenesis: IFNγ is essentially involved while IL-2 plays a minor role. J Invest Dermatol 122, A8Google Scholar
  52. Friedli A, Labarthe MP, Engelhardt E, Feldman R, Salomon D, Saurat JH (1998) Pulse methyprednisolone therapy for severe alopecia areata: an open prospective study of 45 patients. J Am Acad Deramtol 39: 597–602Google Scholar
  53. Friedmann PS (1981) Alopecia areata and autoimmunity. Br J Dermatol 105: 153–157PubMedGoogle Scholar
  54. Friedman PS (1985) Clinical and immunologic association of alopecia areata. Semin Dermatol 4: 9–15Google Scholar
  55. Fülöp E, Vajda Z (1971) Experimentelle Untersuchungen über die therapeutische und schädigende Wirkung der intrafokalen Steroidbehandlung. Dermatol Monatsschr 157: 269–77PubMedGoogle Scholar
  56. Galbraith GM, Thiers BH, Pandey JP (1984) Gm allotype associated resistance and susceptibility to alopecia areata. Clin Exp Immunol 56: 149–52PubMedGoogle Scholar
  57. Galbraith GM, Pandey JP (1989) Km1 allotype association with one subgroup of alopecia areata. Am J Hum Genet 44: 426–8PubMedGoogle Scholar
  58. Galbraith GM, Pandey JP (1995) Tumor necrosis factor alpha (TNF-alpha) gene polymorphism in alopecia areata. Hum Genet 96: 433–6CrossRefPubMedGoogle Scholar
  59. Galbraith GM, Palesch Y, Gore EA, Pandey JP (1999) Contribution of interleukin 1beta and KM loci to alopecia areata. Hum Hered 49: 85–9CrossRefPubMedGoogle Scholar
  60. Gao Q, Rouse TM, Kazmerzak K, Field EH (1999) CD4+CD25+ cells regulate CD8 cell anergy in neonatal tolerant mice. Transplant 68:1891–7CrossRefGoogle Scholar
  61. Gilhar A, Pillar T, Assay B, David M (1992) Failure of passive transfer of serum from patients with alopecia areata and alopecia universalis to inhibit hair growth in transplants of human scalp skin grafted on to nude mice. Br J Dermatol 126:166–71PubMedGoogle Scholar
  62. Gilhar A, Ullmann Y, Berkutzki T, Assy B, Kalish RS (1998) Autoimmune hair loss (alopecia areata) transferred by T lymphocytes to human scalp explants on SCID mice. J Clin Invest 101: 62–7PubMedGoogle Scholar
  63. Gilhar A, Landau M, Assy B, Shalaginov R, Serafimovich S, Kalish RS (2001) Melanocyte-associated T cell epitopes can function as autoantigens for transfer of alopecia areata to human scalp explants on Prkdc(scid) mice. J Invest Dermatol 117:1357–62CrossRefPubMedGoogle Scholar
  64. Gilhar A, Landau M, Assy B, Shalaginov R, Serafimovich S, Kalish RS (2002) Mediation of alopecia areata by cooperation between CD4+ and CD8+ T lymphocytes: transfer to human scalp explants on Prkdc(scid) mice. Arch Dermatol 138: 916–922CrossRefPubMedGoogle Scholar
  65. Gip L, Lodin A, Molin L (1969) Alopecia areata: A follow-up investigation of outpatient material. Acta Derm Venereol 49: 180–8.PubMedGoogle Scholar
  66. Goldshtein LM, Chipizhenko VA (1978) Familial alopecia areata. Vestn Dermatol Venerol 10: 36–8PubMedGoogle Scholar
  67. Gollick H, Orfanos CE (1990) Alopecia areata: pathogenesis and clinical picture. In: Orfanos CE, Happle R, eds. Hair and Hair Diseases. Berlin: Springer-Verlag, 529–69Google Scholar
  68. Gordon PM, Aldridge RD, McVittie E, Hunter JAA (1996) Topical diphencyprone for alopecia areata: evaluation of 48 cases after 30 months’ follow up. Br J Dermatol 134: 869–71CrossRefPubMedGoogle Scholar
  69. Hacham-Zadeh S, Brautbar C, Cohen C, Cohen T (1981) HLA and alopecia areata in Jerusalem. Tissue Antigens 18: 71–4PubMedGoogle Scholar
  70. Happle R (1979) Hinweis zur DNCB-Therapie bei Alopecia areata. Hautarzt 30: 556PubMedGoogle Scholar
  71. Happle R, Echternacht K (1977) Induction of hair growth in alopecia areata with D.N.C.B. Lancet 2:1002–3CrossRefPubMedGoogle Scholar
  72. Happle R, Kalveram KJ, Büchner U, Echternacht-Happle K, Göggelmann W, Summer KH (1980) Contact allergy as a therapeutic tool for alopecia areata: application of squaric acid dibutylester. Dermatologica 161: 289–97PubMedGoogle Scholar
  73. Happle R, Hausen BM, Wiesner-Menzel L (1983) Diphencyprone in the treatment of alopecia areata. Acta Derm Venereol (Stockh) 63: 49–52PubMedGoogle Scholar
  74. Happle R, Perret C, Wiesner-Menzel L (1984) Treatment of alopecia areata with diphencyprone induces hair regrowth and affects the composition of peribulbar infiltrates. In Immunodermatology MacDonald, DM Ed.; Butterworth: London pp. 279–86Google Scholar
  75. Happle R (1985) The potential hazards of dinitrochlorobenzene. Arch Dermatol 121: 330–331CrossRefPubMedGoogle Scholar
  76. Happle R, Klein HM, Macher E (1986) Topical immunotherapy changes the composition of the peribulbar infiltrate in alopecia areata. Arch Dermatol Res 278: 214–8CrossRefPubMedGoogle Scholar
  77. Healy E, Rogers S (1993) PUVA treatment for alopecia areata: does it work? A retrospective review of 102 cases. Br J Dermatol 129:42–4PubMedGoogle Scholar
  78. Hendren S (1949) Identical alopecia areata in identical twins. Arch Dermatol 60: 793–5Google Scholar
  79. Hoffmann R, Wenzel E, Huth A, van der Steen P, Schäufele M, Henninger HP, Happle R (1994) Cytokine mRNA levels in Alopecia areata before and after treatment with the contact allergen diphenylcyclopropenone. J Invest Dermatol 103: 530–3CrossRefPubMedGoogle Scholar
  80. Hoffmann R, Happle R (1996) Topical immunotherapy in alopecai areata: what; how; and why? Dermatol Clin 14: 739–44CrossRefPubMedGoogle Scholar
  81. Hoffmann R, Happle R (1999) Alopecia areata. 1: Clinical aspects, etiology, pathogenesis. Hautarzt 50: W222–31CrossRefPubMedGoogle Scholar
  82. Holsapple MP (2002) Autoimmunity by pesticides: a critical review of the state of the science. Toxicol Lett 127: 101–9CrossRefPubMedGoogle Scholar
  83. Hordinsky MK, Hallgren H, Nelson D, Filipovich AH (1984) Familial alopecia areata. HLA antigens and autoantibody formation in an American family. Arch Dermatol 120: 464–8CrossRefPubMedGoogle Scholar
  84. Hoting E, Boehm A (1992) Therapy of alopecia areata with diphencyprone. Br J Dermatol 127:625–9PubMedGoogle Scholar
  85. Huseby ES, Liggitt D, Brabb T, Schnabel B, Ohlen C, Goverman J (2001) A pathogenic role for myelin-specific CD8(+) T cells in a model for multiple sclerosis. J Exp Med 194: 669–676CrossRefPubMedGoogle Scholar
  86. Ikeda T (1965) A new classification of alopecia areata. Dermatologica 131: 421–45PubMedGoogle Scholar
  87. Jansen BJ, van Ruissen F, Cerneus S, Cloin W, Bergers M, van Erp PE, Schalkwijk J (2003) Tumor necrosis factor related apoptosis inducing ligand triggers apoptosis in dividing but not in differentiating human epidermal keratinocytes. J Invest Dermatol 121: 1433–9CrossRefPubMedGoogle Scholar
  88. Kalkoff KW, Macher E (1958) Über das Nachwachsen der Haare bei der Alopecia areata und maligna nach intracutaner Hydrocortisoninjektion. Hautarzt 9: 441–51PubMedGoogle Scholar
  89. Kavak A, Yesildal N, Parlak AH (2002) Effect of two consecutive earthquakes on outbreaks of alopecia areata. J Dermatol 29: 414–8PubMedGoogle Scholar
  90. Kianto U, Reunala T, Karvonen J, Lassus A, Tiilikainen A (1977) HLA-B12 in alopecia areata. Arch Dermatol 113: 1716CrossRefPubMedGoogle Scholar
  91. Kissler S, Anderton SM, Wraith DC (2001) Antigen-presenting cell activation: a link between infection and autoimmunity? J Autoimmun 16: 303–8CrossRefPubMedGoogle Scholar
  92. Kuntz BM, Selzle D, Braun-Falco O (1977) HLA antigens in alopecia areata. Arch Dermatol 113: 1717CrossRefGoogle Scholar
  93. Larkö O, Swanbeck G (1983) PUVA treatment for alopecia totalis. Acta Derm Venereol (Stockh) 63: 546–9PubMedGoogle Scholar
  94. Larsson M, Fonteneau JF, Bhardwaj N (2001) Dendritic cells resurrect antigens from dead cells. Trends Immunol 22: 141–8CrossRefPubMedGoogle Scholar
  95. Lassus A, Eskelinen A, Johansson E (1984) Treatment of alopecia areata with three different PUVA modalities. Photodermatology 1: 141–4PubMedGoogle Scholar
  96. Lehnert W Zur Lokalbehandlung schwerer Formen der Alopecia areata mit Kortikosteroidsalbe (1974) Dermatol Monatsschr 160: 396–8PubMedGoogle Scholar
  97. Lévy-Franckel A, Juster E La pelade (1925) J de Medecine de Paris 44: 631–5Google Scholar
  98. Leyden JJ, Kligman AM (1972) Treatment of alopcia areata with steroid solution. Arch Derm 106: 924CrossRefGoogle Scholar
  99. Liakopoulou M, Alifieraki T, Katideniou A, Kakourou T, Tselalidou E, Tsiantis J, Stratigos J (1997) Children with alopecia areata: psychiatric symptomatology and life events. J Am Acad Child Adolesc Psychiatry 36: 678–84CrossRefPubMedGoogle Scholar
  100. Lindner G, Botchkarev VA, Botchkareva NV, Ling G, van der Veen C, Paus R (1997) Analysis of apoptosis during hair follicle regression (catagen). Am J Pathol 151:1601–17PubMedGoogle Scholar
  101. Ludewig B, Junt T, Hengartner H, Zinkernagel RM (2001) Dendritic cells in autoimmune diseases. Curr Opin Immunol 13: 657–62CrossRefPubMedGoogle Scholar
  102. Lutz G, Bauer R (1988) Autoimmunity in alopecia areata: An assessment in 100 patients. Hautarzt 39: 5–11.PubMedGoogle Scholar
  103. Macdonald Hull S, Cunliffe WJ (1991) Successful treatment of alopecia areata using the contact allergen diphencyprone. Br J Dermatol 124: 212–3Google Scholar
  104. Macdonald Hull S, Norris JF (1988) Diphencyprone in the treatment of long-standing alopecia areata. Br J Dermatol 119: 367–74PubMedGoogle Scholar
  105. Macdonald Hull S, Pepall L, Cunliffe WJ (1991) Alopecia areata in children: response to treatment with diphencyprone. Br J Dermatol 125: 164–8PubMedGoogle Scholar
  106. Main RA, Robbie RB, Gray ES, Donald D, Horne CH (1975) Smooth muscle antibodies and alopecia areata. Br J Dermatol 92: 389–93PubMedGoogle Scholar
  107. Maitland JM, Alridge RD, Main RA, White MI, Ormerod AD (1984) Topical minoxidil in the treatment of alopecia areata. Br Med J 288: 794Google Scholar
  108. McDonagh AJ, Messenger AG (1996) The pathogenesis of alopecia areata. Dermatol Clin 14: 661–70CrossRefPubMedGoogle Scholar
  109. McElwee KJ, Pickett P, Oliver RF (1996a) The DEBR rat, alopecia areata and autoantibodies to the hair follicle. Br J Dermatol 134: 55–63CrossRefPubMedGoogle Scholar
  110. McElwee KJ, Spiers EM, Oliver RF (1996b) In vivo depletion of CD8+ T cells restores hair growth in the DEBR model for alopecia areata. Br J Dermatol 135: 211–7CrossRefPubMedGoogle Scholar
  111. McElwee KJ, Boggess D, King LE Jr, Sundberg JP (1998a) Experimental induction of alopecia areata-like hair loss in C3H/HeJ mice using full-thickness skin grafts. J Invest Dermatol 111: 797–803CrossRefPubMedGoogle Scholar
  112. McElwee KJ, Boggess D, Olivry T, Oliver RF, Whiting D, Tobin DJ, Bystryn JC, King LE Jr, Sundberg JP (1998b) Comparison of alopecia areata in human and nonhuman mammalian species. Pathobiology 66: 90–107CrossRefPubMedGoogle Scholar
  113. McElwee KJ, Bristol IJ, Boggess D, Leiter EH, King LE Jr, Elson CO, Cong Y, Sundberg JP (1999a) A common disease susceptibility gene locus for development of alopecia areata and/or colitis in C3H/HeJ mice. J Invest Dermatol Symp Proc 4: 249Google Scholar
  114. McElwee KJ, Spiers EM, Oliver RF (1999b) Partial restoration of hair growth in the DEBR model for Alopecia areata after in vivo depletion of CD4+ T cells. Br J Dermatol 140: 432–7CrossRefPubMedGoogle Scholar
  115. McElwee KJ, Tobin DJ, Bystryn JC, King LE Jr, Sundberg JP (1999c) Alopecia areata: An autoimmune disease? Exp Dermatol 8: 371–9PubMedGoogle Scholar
  116. McElwee K, Freyschmidt-Paul P, Ziegler A, Happle R, Hoffmann R (2001a) Genetic susceptibility and severity of alopecia areata in human and animal models. Eur J Dermatol 11: 11–6CrossRefPubMedGoogle Scholar
  117. McElwee KJ, Silva K, Beamer WG, King LE Jr, Sundberg JP (2001b) Melanocyte and gonad activity as potential severity modifying factors in C3H/HeJ mouse alopecia areata. Exp Dermatol 10: 420–429CrossRefPubMedGoogle Scholar
  118. McElwee KJ, Hoffmann R (2002a) Alopecia areata — animal models. Clin Exp Dermatol 27:414–21CrossRefGoogle Scholar
  119. McElwee KJ, Hoffmann R, Freyschmidt-Paul P, Wenzel E, Kissling S, Sundberg JP, Zöller M (2002b) Resistance to alopecia areata in C3H/HeJ mice is associated with increased expression of regulatory cytokines and a failure to recruit CD4+ and CD8+ cells. J Invest Dermatol 119: 1426–33CrossRefPubMedGoogle Scholar
  120. McElwee KJ, Niiyama S, Freyschmidt-Paul P, Wenzel E, Kissling S, Sundberg JP, Hoffmann R (2003a) Dietary soy oil content and soy-derived phytoestrogen genistein increase resistance to alopecia areata onset in C3H/HeJ mice. Exp Dermatol 12: 30–6CrossRefPubMedGoogle Scholar
  121. McElwee KJ, Silva K, Boggess D, Bechtold L, King LE Jr, Sundberg JP (2003b) Alopecia areata in C3H/HeJ mice involves leukocyte-mediated root sheath disruption in advance of overt hair loss. Vet Pathol 40: 643–50CrossRefPubMedGoogle Scholar
  122. McElwee KJ, Freyschmidt-Paul P, Hoffmann R, Kissling S, Hummel S, Vitacolonna M, Zöller M Transfer of CD8+ cells induce localized hair loss while CD4+/CD25-cells promote systemic alopecia areata and CD4+/CD25+ cells blockade disease onset in the C3H/HeJ mouse model. J Invest Dermatol (in press)Google Scholar
  123. Mehlman RD, Griesemer RD (1968) Alopecia areata in the very young. Am J Psychiatry 125:605–14PubMedGoogle Scholar
  124. Messenger AG, Bleehen SS (1985) Expression of HLA-DR by anagen hair follicles in alopecia areata. J Invest Dermatol 85: 569–72CrossRefPubMedGoogle Scholar
  125. Messenger AG, Simpson NB (1997) Alopecia areata. In: Diseases of the hair and scalp. Dawber R, ed.; Blackwell Science Oxford pp. 338–69Google Scholar
  126. Micali G, Cicero RL, Nasca MR, Sapuppo A (1996) Treatment of alopecia areata with squaric acid dibutylester. Int J Dermatol 35: 52–6PubMedGoogle Scholar
  127. Michie HJ, Jahoda CA, Oliver RF, Johnson BE (1991) The DEBR rat: An animal model of human alopecia areata. Br J Dermatol 125: 94–100PubMedGoogle Scholar
  128. Milgraum SS, Mitchell AJ, Bacon GE, Rasmussen JE (1987) Alopecia areata, endocrine function, and autoantibodies in patients 16 years of age or younger. J Am Acad Dermatol 17:57–61PubMedGoogle Scholar
  129. Mitchell AJ, Douglass MC (1985) Topical photochemotherapy for alopecia areata. J Am Acad Dermatol 12: 644–9PubMedGoogle Scholar
  130. Monk B (1989) Induction of hair growth in alopecia totalis with diphencyprone sensitization: Clin Exp Dermtol 14: 154–7Google Scholar
  131. Montes LF (1977) Topical halcinonide in alopecia areata and in alopecia totalis. J Cut Pathol 4: 47–50Google Scholar
  132. Morling N, Frentz G, Fugger L, Georgsen J, Jakobsen B, Odum N, Svejgaard A (1991) DNA polymorphism of HLA class II genes in alopecia areata. Dis Markers 9: 35–42PubMedGoogle Scholar
  133. Motyka B, Korbutt G, Pinkoski MJ, Heibein JA, Caputo A, Hobman M, Barry M, Shostak I, Sawchuk T, Holmes CF, Gauldie J, Bleackley RC (2000) Mannose 6-phosphate/insulin-like growth factor II receptor is a death receptor for granzyme B during cytotoxic T cell-induced apoptosis. Cell 103: 491–500CrossRefPubMedGoogle Scholar
  134. Muller SA, Winkelmann RK (1963) Alopecia areata: An evaluation of 736 patients. Arch Dermatol 88: 290–7PubMedGoogle Scholar
  135. Nelson DA, Spielvogel RL (1985) Anthralin therapy fo alopecia areata. Int J Dermatol 24:606–7PubMedGoogle Scholar
  136. Nutbrown M, MacDonald Hull SP, Baker TG, Cunliffe WJ, Randall VA (1996) Ultrastructural abnormalities in the dermal papillae of both lesional and clinically normal follicles from alopecia areata scalps. Br J Dermatol 135: 204–10CrossRefPubMedGoogle Scholar
  137. Ochsendorf FR, Mitrou G, Milbradt R (1988) Therapie der Alopecia Areata mit Diphenylcyclopropenone. Z Hautkr 63: 94–100PubMedGoogle Scholar
  138. Olivetti L, Bubola D(1965) Clinical observations on 160 cases of "area celsi"./G It Dermatol Minerva Dermatol 106: 367–72.Google Scholar
  139. Orecchia G, Belvedere MC, Martinetti M, Capelli E, Rabbiosi G (1987) Human leukocyte antigen region involvement in the genetic predisposition to alopecia areata. Dermatologica 175: 10–14PubMedGoogle Scholar
  140. Orentreich N, Sturm HM, Weidman AI, Pelzig A (1960) Local Injection of steroids and hair regrowth in alopecias. Arch Dermatol 82: 894–902PubMedGoogle Scholar
  141. Parakkal PF (1969) Role of macrophages in collagen resorption during hair growth cycle. J Ultrastruct Res 29: 210–7CrossRefPubMedGoogle Scholar
  142. Pascher F, Kurtin S, Andrade R (1970) Assay of 0.2% fluocinolone acetonide cream for alopecia areata and totalis. Dermatologica 141: 193–202PubMedGoogle Scholar
  143. Paus R, Slominski A, Czarnetzki BM (1993) Is alopecia areata an autoimmune-response against melanogenesis-related proteins, exposed by abnormal MHC class I expression in the anagen hair bulb? Yale J Biol Med 66: 541–54PubMedGoogle Scholar
  144. Paus R (1996) Control of the hair cycle and hair diseases as cycling disorders. Curr Opin Dermatol 3: 248–58Google Scholar
  145. Paus R, Christoph T, Muller-Rover S (1999) Immunology of the hair follicle: a short journey into terra incognita. J Investig Dermatol Symp Proc 4: 226–34PubMedGoogle Scholar
  146. Penders AJ (1968) Alopecia areata and atopy. Dermatologica 136: 395–9PubMedGoogle Scholar
  147. Perret C, Wiesner-Menzel L, Happle R (1984) Immunohistochemical analysis of T-cell subsets in the peribulbar and intrabulbar infiltrates of alopecia areata. Acta Derm Venereol 64: 26–30PubMedGoogle Scholar
  148. Perret CM, Steijlen PM, Happle R (1990) Erythema multiforme-like eruptions: a rare side effect of topical immunotherapy with diphenylcyclopropenone. Dermatologica 180: 5–7PubMedGoogle Scholar
  149. Perriard-Wolfensberger J, Pasche-Koo F, Mainetti C, Labarthe MP, Salomon D, Saurat J (1993) Pulse of methylprednisolone in alopecia areata. Dermatology 187: 282–5PubMedGoogle Scholar
  150. Phinck E P, Peereboom-Wynia J D, Vuzevski V D, Westerhof W, Stolz E (1993) Tuming white overnight, is it possible? Ned Tijdschr Geneeskd 137: 207–10Google Scholar
  151. Porter D, Burton JL (1971) A comparison of intra-lesional triamcinolone hexacetonide and triamcinolone acetonide in alopecia areata. Br J Dermatol 85: 272PubMedGoogle Scholar
  152. Price VH (1987a) Double-blind, placebo-controlled evaluation of topical minoxidil in extensive alopecia areata. J Am Acad Dermatol 16: 730–36PubMedGoogle Scholar
  153. Price VH (1987b) Topical minoxidil (3 %) in extensive alopecia areata, including long-term efficacy. J Am Acad Dermatol 16: 737–44PubMedGoogle Scholar
  154. Puavilai S, Puavilai G, Charuwichitratana S, Sakuntabhai A, Sriprachya-Anunt S. (1994) Prevalence of thyroid diseases in patients with alopecia areata. Int J Dermatol 33: 632–3PubMedGoogle Scholar
  155. Ranchoff RE, Bergfeld WF, Steck WD, Subichin SJ (1989) Extensive alopecia areata. Results of treatment with 3% topical minoxidil. Cleve Clin J Med 56: 149–154PubMedGoogle Scholar
  156. Randall VA (2001) Is alopecia areata an autoimmune disease? Lancet 358: 1922–24CrossRefPubMedGoogle Scholar
  157. Ranki A, Kianto U, Kanerva L, Tolvanen E, Johansson E (1984) Immunohistochemical and electron microscopic characterization of the cellular infiltrate in alopecia (areata, totalis, and universalis). J Invest Dermatol 83: 7–11CrossRefPubMedGoogle Scholar
  158. Ro BI (1995) Alopecia areata in Korea (1982–1994) J Dermatol 22: 858–64.PubMedGoogle Scholar
  159. Russell JH, Ley TJ (2002) Lymphocyte-mediated cytotoxicity. Annu Rev Immunol 20: 323–70CrossRefPubMedGoogle Scholar
  160. Sabouraud R (1913) Nouvelles recherches sur l’etiologie de la pelade (pelade et menopause). Annales de Dermatologie et de syphiligraphie 5: 88–97Google Scholar
  161. Sabouraud R (1896) Sur les origines de la pelade. Annales de Dermatologie et syphiligraphie 3:253–77Google Scholar
  162. Sabouraud R (1929) Sur l’etiologie de la pelade Arch Dermato-Syphiligr Clin Hop St Louis 1:31–49Google Scholar
  163. Safavi KH, Muller SA, Suman VJ, Moshell AN, Melton LJ 3rd (1995) Incidence of alopecia areata in Olmsted County, Minnesota, 1975 through 1989. Mayo Clin Proc 70: 628–33PubMedGoogle Scholar
  164. Salamon T, Musafija A, Milicevic M (1971) Alopecia areata and diseases of the thyroid gland. Dermatologica 142: 62–3PubMedGoogle Scholar
  165. Sauder DN, Bergfeld WF, Krakauer RS (1980) Alopecia areata: An inherited autoimmune disease. In: Hair, trace elements and human disease Brown AC, Crounse AG eds. New York: Praeger, 343.Google Scholar
  166. Scerri L, Pace JL (1992) Identical twins with identical alopecia areata. J Am Acad Dermatol 27:766–7PubMedGoogle Scholar
  167. Schallreuter KU, Lemke R, Brandt O, Schwartz R, Westhofen M, Montz R, Berger J (1994) Vitiligo and other diseases: coexistence or true association? Hamburg study on 321 patients. Dermatology 188: 269–75PubMedGoogle Scholar
  168. Schroder K, Hertzog PJ, Ravasi T, Hume DA (2004) Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 75: 163–89CrossRefPubMedGoogle Scholar
  169. Schulz A, Hamm H, Weiglein U, Axt M, Bröcker EB (1996) Dexamethasone pulse therapy in severe long-standing alopecia areata: a treatment failure. Eur J Dermatol 6: 26–9Google Scholar
  170. Schuttelaar M-LA, Hamstra JJ, Plinck E.P, Peereboom-Wynia JDR, Vuzevski VD, Mulder PGH, Oranje AP (1996) Alopecia areata in children: treatment with diphencyprone. Br J Dermatol 135: 581–5CrossRefPubMedGoogle Scholar
  171. Seiter S, Ugurel S, Tilgen W, Reinhold U (2001) High-Dose pulse corticosteroid therapy in the treatment of severe alopecia areata. Dermatology 202: 230–234CrossRefPubMedGoogle Scholar
  172. Sharma VK (1996) Pulsed administration of corticosteroids in the treatment of alopecia areata. Int J Dermatol 35: 133–136PubMedGoogle Scholar
  173. Sharma VK, Dawn G, Kumar B (1996a) Profile of alopecia areata in Northern India. Int J Dermatol 35: 22–7PubMedGoogle Scholar
  174. Sharma VK, Kumar B, Dawn G (1996b) A clinical study of childhood alopecia areata in Chandigarh, India. Pediatr Dermatol 13: 372–7PubMedGoogle Scholar
  175. Sharma VK, Muralidhar S (1998) Treatment of widespread alopecia areata in young patients with monthly oral corticosteroid pulse. Pediatr Dermatol 15: 313–317CrossRefPubMedGoogle Scholar
  176. Shellow WV, Edwards JE, Koo JY (1992) Profile of alopecia areata: A questionnaire analysis of patient and family. Int J Dermatol 31: 186–9PubMedGoogle Scholar
  177. Shelton JM, Hollander L (1942) Alopecia totalis in father and daughter. Arch Dermatol Syph 46: 137–8Google Scholar
  178. Siegel RM, Chan FK, Chun HJ, Lenardo MJ (2000) The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity. Nat Immunol 1: 469–74PubMedGoogle Scholar
  179. Stankler L (1979) Synchronous alopecia areata in two siblings: a possible viral aetiology. Lancet 1: 1303–4CrossRefGoogle Scholar
  180. Stewart MI, Smoller BR (1993) Alopecia universalis in an HIV-positive patient: possible insight into pathogenesis. J Cutan Pathol 20:180–3PubMedGoogle Scholar
  181. Sundberg JP, Boggess D, Silva KA, McElwee KJ, King LE, Li R, Churchill G, Cox GA (2003) Major locus on mouse chromosome 17 and minor locus on chromosome 9 are linked with alopecia areata in C3H/HeJ mice. J Invest Dermatol. 120: 771–5CrossRefPubMedGoogle Scholar
  182. Sundberg JP, Cordy WR, King LE Jr. (1994) Alopecia areata in aging C3H/HeJ mice. J Invest Dermatol 102: 847–56CrossRefPubMedGoogle Scholar
  183. Suri-Payer E, Amar AZ, Thornton AM, Shevach EM (1998) CD4+CD25+ T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. J Immunol 160: 1212–8PubMedGoogle Scholar
  184. Tarlow JK, Clay FE, Cork MJ, Blakemore AI, McDonagh AJ, Messenger AG, Duff GW. (1994) Severity of alopecia areata is associated with a polymorphism in the interleukin-1 receptor antagonist gene. J Invest Dermatol 103: 387–90CrossRefPubMedGoogle Scholar
  185. Taylor CR, Hawk JLM (1995) PUVA treatment of alopecia areata partialis, totalis and universalis: audit of 10 years’ experience at St John’s Institute of Dermatology. Br J Dermatol 133: 914–8PubMedGoogle Scholar
  186. Tobin DJ, Orentreich N, Bystryn JC (1994a) Autoantibodies to hair follicles in normal individuals. Arch Dermatol 130: 395–6CrossRefPubMedGoogle Scholar
  187. Tobin DJ, Orentreich N, Fenton DA, Bystryn JC (1994b) Antibodies to hair follicles in alopecia areata. J Invest Dermatol 102: 721–4CrossRefPubMedGoogle Scholar
  188. Tobin DJ, Sundberg JP, King LE Jr, Boggess D, Bystryn JC (1997) Autoantibodies to hair follicles in C3H/HeJ mice with alopecia areata-like hair loss. J Invest Dermatol 109: 329–33CrossRefPubMedGoogle Scholar
  189. Tobin DJ, Alhaidari Z, Olivry T (1998) Equine alopecia areata autoantibodies target multiple hair follicle antigens and may alter hair growth. A preliminary study. Exp Dermatol 7:289–97PubMedGoogle Scholar
  190. Tobin DJ (2003) Characterization of hair follicle antigens targeted by the anti-hair follicle immune response. J Investig Dermatol Symp Proc 8: 176–81CrossRefPubMedGoogle Scholar
  191. Tosti A, Piraccini B, Pazzaglia M, Vincenzi C (2003) Clobetasol propionate 0.05% under occlusion in the treatment of alopecia totalis/universalis. J Am Acad Dermatol 49: 96–98CrossRefPubMedGoogle Scholar
  192. Valsecchi R, Vicari O, Frigeni A, Foiadelli L, Naldi L, Cainelli T (1985) Familial alopecia areata — genetic susceptibility or coincidence? Acta Derm Venereol 65: 175–7PubMedGoogle Scholar
  193. Van der Steen PH, Baar van JMJ, Perret C, Happle R (1991) Treatment of alopecia areata with diphenylcyclopropenone. J Am Acad Dermatol 24: 253–7PubMedGoogle Scholar
  194. Van der Steen P, Traupe H, Happle R, Boezeman J, Strater R, Hamm H (1992a) The genetic risk for alopecia areata in first degree relatives of severely affected patients. Acta Derm Venereol (Stockh) 72: 373–5PubMedGoogle Scholar
  195. Van der Steen PH, Happle R (1992b) Dyschromia in confetti as a side effect of topical immunotherapy with diphenylcyclopropenone. Arch Dermatol 128: 518–20CrossRefPubMedGoogle Scholar
  196. Van der Veen EE, Ellis CN, Kang S, Case P, Headington JT, Voorhees JJ, Swanson NA (1984) Topical minoxidil for hair regrowth. J Am Acad Dermatol 11: 416–421PubMedGoogle Scholar
  197. Verbov J (1973) Steroid solution treatment of alopecia areata. Arch Derm 108:135CrossRefGoogle Scholar
  198. Vestey JP, Savin JA (1986) A trial of 1% minoxidil used topically for severe alopecia areata. Acta Derm Venereol (Stockh) 66: 179–80PubMedGoogle Scholar
  199. Vogel F, Motulsky AG (1997) Human Genetics: Problems and Approaches. 3rd ed. Berlin: Springer-Verlag, 223–6Google Scholar
  200. Walker SA, Rothman S (1950) Alopecia areata. A statistical study and consideration of endocrine influences. J Invest Dermatol 14: 403–413PubMedGoogle Scholar
  201. Weedon D, Strutton G (1981) Apoptosis as the mechanism of the involution of hair follicles in catagen transformation. Acta Derm Venereol 61: 335–9PubMedGoogle Scholar
  202. Weidman AI, Zion LS, Mamelok AE (1956) Alopecia areata occurring simultaneously in identical twins. Arch Dermatol 74: 424–6Google Scholar
  203. Weise K, Kretzschmar L, John SM, Hamm H (1996) Topical immunotherapy in alopecia areata: anamnestic and clinical criteria of prognostic significance. Dermatology 192:129–133PubMedGoogle Scholar
  204. Weiss VC, West DP, Fu TS, Robinson LA, Cook B, Cohen RL, Chambers DA (1984) Alopecia areata treated with topical minoxidil. Arch Dermatol 120: 457–63CrossRefPubMedGoogle Scholar
  205. Weitgasser H (1968) Erfahrungen mit einer Triamcinolon-Tinktur bei entzündlichen Dermatosen. Z Hautkr 43: 505–8Google Scholar
  206. Welsh EA, Clark HH, Epstein SZ, Reveille JD, Duvic M (1994) Human leukocyte antigen-DQB1 *03 alleles are associated with alopecia areata. J Invest Dermatol 103: 758–63CrossRefPubMedGoogle Scholar
  207. Westgate GE, Craggs RI, Gibson WT (1991) Immune privilege in hair growth. J Invest Dermatol 97: 417–420CrossRefPubMedGoogle Scholar
  208. White SI, Friedmann PS (1985) Topical minoxidil lacks efficacy in alopecia areata. Arch Dermatol 121: 591CrossRefPubMedGoogle Scholar
  209. Whitmont K, Cooper A (2003) PUVA treatment of alopecia areata totalis and universalis: a retrospective study. Australas J Dermatol 44: 106–109CrossRefPubMedGoogle Scholar
  210. Wiseman MC, Shapiro J, MacDonald N, Lui H (2001) Predictive model for immunotherapy of alopecia areata with diphencyprone. Arch Dermatol 137: 1063–1068PubMedGoogle Scholar
  211. Wucherpfennig KW (2001) Mechanisms for the induction of autoimmunity by infectious agents. J Clin Invest 108: 1097–104CrossRefPubMedGoogle Scholar
  212. Wunderlich C, Braun-Falco O (1965) Mongolismus und Alopecia areata. Med Welt 10:477–81PubMedGoogle Scholar
  213. Zandman-Goddard G, Shoenfeld Y (2002) HIV and autoimmunity. Autoimmun Rev 1: 329–37CrossRefPubMedGoogle Scholar
  214. Zhang JG, Oliver RF (1994) Immunohistological study of the development of the cellular infiltrate in the pelage follicles of the DEBR model for alopecia areata. Br J Dermatol 130:405–14PubMedGoogle Scholar
  215. Zlotogorski A, Weinrauch L, Brautbar C (1990) Familial alopecia areata: No linkage with HLA. Tissue Antigens 36: 40–1PubMedGoogle Scholar
  216. Zöller M, McElwee KJ, Engel P, Hoffmann R (2002) Transient CD44 variant isoform expression and reduction in CD4(+)/CD25(+) regulatory T cells in C3H/HeJ mice with alopecia areata. J Invest Dermatol 118: 983–92CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Wien 2005

Authors and Affiliations

  • Pia Freyschmidt-Paul
  • Kevin McElwee
  • Rolf Hoffmann

There are no affiliations available

Personalised recommendations